Advisornet Financial’s Akebia Therapeutics AKBA Stock Holding History

Advisornet Financial’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,000	Closed	-$6.2K	–	2049
2023 Q4	$6.2K	Hold	5,000	–	–	﹤0.01%	1445
2023 Q3	$5.7K	Hold	5,000	–	–	﹤0.01%	1392
2023 Q2	$4.58K	Hold	5,000	–	–	﹤0.01%	1527
2023 Q1	$2.8K	Hold	5,000	–	–	﹤0.01%	1616
2022 Q4	$2.88K	Hold	5,000	–	–	﹤0.01%	1587
2022 Q3	$2K	Hold	5,000	–	–	﹤0.01%	1648
2022 Q2	$2K	Hold	5,000	–	–	﹤0.01%	1661
2022 Q1	$4K	Buy	+5,000	New	+$10.7K	﹤0.01%	1645
2019 Q2	–	Sell	-975	Closed	-$8K	–	1676
2019 Q1	$8K	Hold	975	–	–	﹤0.01%	1221
2018 Q4	$5K	Hold	975	–	–	﹤0.01%	1218
2018 Q3	$9K	Hold	975	–	–	﹤0.01%	1137
2018 Q2	$10K	Hold	975	–	–	﹤0.01%	1132
2018 Q1	$9K	Buy	+975	New	+$13.6K	﹤0.01%	1111

Other funds holding AKBA

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Advisornet Financial's AKBA Position: Q1 2024 in Review

Advisornet Financial sold out of Akebia Therapeutics (AKBA) in Q1 2024, closing a stake of 5,000 shares — an estimated $6.2K sold.

Advisornet Financial first reported a position in AKBA in Q1 2018 and held it in 13 quarters. The position peaked at $10K in Q2 2018. 114 funds tracked by Wall St. Rank hold AKBA as of Q1 2024.

Advisornet Financial reported no remaining Akebia Therapeutics position as of Q1 2024 after selling out during the quarter.
Advisornet Financial sold 5,000 Akebia Therapeutics shares in Q1 2024, an estimated $6.2K.
Advisornet Financial first reported a position in Akebia Therapeutics in Q1 2018 and held it in 13 quarters.
Advisornet Financial's Akebia Therapeutics position peaked at $10K in Q2 2018.
114 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2024.

Based on Advisornet Financial's 13F filing for Q1 2024, filed 12 Apr 2024.